At Elixir Pharma, we are proud to collaborate with BioGeneric Pharma (BGP), a pioneering Egyptian biopharmaceutical company backed by multinational shareholders.
With a clear mission to provide high-quality therapeutic products and preventive vaccines, BioGenerics has positioned itself as a key player in advancing healthcare both locally and regionally.

This collaboration reflects our shared vision of driving innovation and expanding access to advanced medicines.
By aligning BioGenerics’ strong production capabilities — from monoclonal antibodies and insulin analogues to preventive vaccines — with Elixir’s market expertise and reach, we are working together to bring high-impact solutions to patients in Egypt and beyond.

A cornerstone of BioGenerics’ innovation journey is its leadership in mRNA technology transfer, undertaken in partnership with the World Health Organization and global research hubs.
With dedicated R&D facilities, advanced production technologies, and a commitment to international quality standards, BioGenerics is at the forefront of introducing next-generation therapies that address both current and future health challenges.

Together, Elixir and BioGenerics are building a collaboration rooted in innovation, responsibility, and the pursuit of progress.
By combining our strengths, we aim not only to expand the horizons of Egypt’s pharmaceutical industry but also to contribute to a healthier tomorrow for communities across the region.